Schaeffer's Top Stock Picks for '25

Analyst Upgrades: Apple, Sarepta Therapeutics, Gilead

Analysts upwardly revised their ratings and price targets on Apple Inc. (NASDAQ:AAPL), Sarepta Therapeutics Inc (NASDAQ:SRPT), and Gilead Sciences, Inc. (NASDAQ:GILD)

Apr 6, 2016 at 9:21 AM
facebook X logo linkedin


Analysts are weighing in on iPhone maker Apple Inc. (NASDAQ:AAPL), as well as biotech stocks Sarepta Therapeutics Inc (NASDAQ:SRPT) and Gilead Sciences, Inc. (NASDAQ:GILD). Here's a quick roundup of today's bullish brokerage notes on AAPL, SRPT, and GILD.
 
  • More bullish attention is coming AAPL's way, as Needham started coverage with a "strong buy" recommendation, on top of a $150 price target -- all-time-high territory. This is just more of the same for AAPL, as 81% of brokerage firms already recommend buying it. After bouncing around the $92-$98 zone at the beginning of 2016, Apple Inc. has hit its stride, gaining 13.6% since the end of February to trade at $109.81. In fact, AAPL now sits near overbought territory, according to its 14-day Relative Strength Index (RSI) of 68. 
  • SRPT is set to pop 7.4% when the market opens, thanks to Oppenheimer's bullish note. The brokerage firm hiked its price target to $60 from $45, representing territory not explored in 14 years, and over three times the stock's Tuesday close at $19.53. Oppenheimer said it expects the Food and Drug Administration (FDA) to rule favorably on Sarepta Therapeutics Inc's drug eteplirsen late next month. Skepticism is rising in other areas, though, with short interest increasing 11.1% in the last two reporting periods, putting a stunning 35% of SRPT's float in short sellers' control. 
  • GILD has found new life on the charts recently, breaking out of the $87-$91 range that contained the shares for over a month. Plus, the stock's close at $95.57 on Tuesday marked its first finish above the 100-day moving average -- a strong level of resistance in late 2015 -- since late October. Jefferies has responded to this technical strength with a price-target hike to $101. Options traders also have high expectations. Specifically, Gilead Sciences, Inc.'s 50-day call/put volume ratio at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) comes in at 2.92 -- just 4 percentage points from an annual high. 
Sign up now for Schaeffer's Opening View newsletter to get a head start on all the major pre-market news!
 
 

Which of These SUB-$5 Stocks Could 26x From Here? (AD)

He called a rare 11x on Tesla…

Then he called a 26x on Workhorse…

Then an even rarer 35x on Nio Inc…

Now Tim Bohen says these 5 tiny “America First” stocks are next up in 2025.

They’re trading for less than $5 right now.

But thanks to Elon & Trump’s new alliance…

They could be off to the races in Trump’s first 100 days.

And right now for a limited time…

You can get the names & tickers for just $1 here. (AD)

10 Stock Picks FREE
 
 

Featured Articles from Trusted Partners:

🚀 One Stock Pick Could Change Everything in 2025
What if one stock pick could define your success next year? Get 10 expert-vetted stocks set for 2025—plus 5 bonus picks to watch now. Get the Report →

🆕 New Options Need New Trading Strategies
Zero-DTE options are the newest (and hottest) options to trade.  Professional traders have rushed into the market and are making a mint.  Don’t get left behind - learn all about these options, how to trade them, market setups to profit from, plus much more. Download now →

👀 Revealed: 3 Defensive Stocks for Your Portfolio
Worried about the market? This free report reveals 3 under-the-radar defensive stocks for uncertain times in any kind of economy.

 

 
 

FREE Report Download

 

Follow us on X, Follow us on Twitter